SCANCELL HOLDINGS PLC

• ⚠

  Material uncertainty over going concern

  Excluding potential financing from these sources, the Group's two-year cash flow forecast to 30 April 2027 with cash preservation measures in areas of uncommitted expenditure suggests it could continue to operate with cash currently held until August 2026, which is less than a year from the date of approval of these financial statements... material uncertainties therefore exist which may cast significant doubt on its ability to continue as a going concern.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

UK-adopted International Accounting Standards

Reporting scope

Consolidated group

Auditor

RSM UK Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“Excluding potential financing from these sources, the Group's two-year cash flow forecast to 30 April 2027 with cash preservation measures in areas of uncommitted expenditure suggests it could continue to operate with cash currently held until August 2026, which is less than a year from the date of approval of these financial statements... material uncertainties therefore exist which may cast significant doubt on its ability to continue as a going concern.”

Group structure

1. SCANCELL HOLDINGS PLC · parent
   1. GlyMab Therapeutics Limited

Significant events

• “In June 2025, the Company incorporated a wholly owned subsidiary, GlyMab Therapeutics Limited, with the intention to hold and develop an early-stage pipeline of high affinity GlyMab ® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab.”
• “In September 2025, the Company agreed to an early partial redemption of £1.0 million of the 3% unsecured Convertible Loan Notes ("CLNs") held by Redmile. The total amount of the CLNs which remains outstanding following the early partial redemption will be £18.2 million. The redemption will be satisfied from the Group's existing cash resources.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

4

last 24 months

Officers appointed

1

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  +14%

  £14,817,000 → £16,894,000

• Net assets

  -9.4%

  -£3,505,000 → -£3,835,000

• Employees

  -1.6%

  61 → 60

• Operating profit

  +17.9%

  -£18,267,000 → -£15,001,000

• Profit before tax

  -67.9%

  -£9,117,000 → -£15,303,000

• Wages

  +9%

  £4,456,000 → £4,856,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers